ASCO 2021 Lung Cancer - Physician's Weekly


Advertisement

ASCO 2021 Lung Cancer

5-year PACIFIC data hold strong in NSCLC

Updated findings of the PACIFIC trial showed an overall survival (OS) rate of 43% after 5 years of treatment with durvalumab, which has . Physician’s Weekly spoke with Dr. Camille Hertzka, vice president and head of Oncology, US...

Read More

Advertisement

Advertisement

For latest news and updates
Email-id is invalid